Zacks Investment Research upgraded shares of Abcam (OTCMKTS:ABCZY) from a hold rating to a buy rating in a research report released on Wednesday. They currently have $18.00 price target on the stock.
According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “
Shares of Abcam (OTCMKTS ABCZY) opened at $15.91 on Wednesday. Abcam has a twelve month low of $9.60 and a twelve month high of $16.08.
COPYRIGHT VIOLATION NOTICE: “Abcam (ABCZY) Stock Rating Upgraded by Zacks Investment Research” was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thelincolnianonline.com/2018/01/14/abcam-abczy-stock-rating-upgraded-by-zacks-investment-research.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.